Skip to main content
Erschienen in: Supportive Care in Cancer 10/2013

01.10.2013 | Original Article

Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia

verfasst von: Chris L. Pashos, Christopher R. Flowers, Neil E. Kay, Mark Weiss, Nicole Lamanna, Charles Farber, Susan Lerner, Jeff Sharman, David Grinblatt, Ian W. Flinn, Mark Kozloff, Arlene S. Swern, Thomas K. Street, Kristen A. Sullivan, Gale Harding, Zeba M. Khan

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This analysis examined associations between gender and health-related quality of life (HRQOL) in patients with B-cell chronic lymphocytic leukemia (CLL) as they initiate therapy for CLL outside the clinical trial setting.

Methods

Baseline data were collected as part of Connect® CLL Registry, a prospective observational study initiated in community, academic, and government centers. Patient demographics and clinical characteristics were provided by clinicians. Patients reported HRQOL using the Brief Fatigue Inventory (BFI), EQ-5D, and Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Mean scores were analyzed, with statistical significance of differences determined by ANOVA. Multivariate analysis also considered age and line of therapy.

Results

Baseline HRQOL data were available for 1,140 patients: 710 (62 %) men and 430 (38 %) women from 161 centers. Patients were predominantly white (89 %) with mean age 69 ± 11 years. Women reported significantly worse global fatigue (P <0.0001), fatigue severity (P <0.0001), and fatigue-related interference (P = 0.0005) versus men (BFI). Pain/discomfort (P = 0.0077), usual activities (P = 0.0015), and anxiety/depression (P = 0.0117) were significantly worse in women than in men (EQ-5D). With women reporting a better social/family score (P = 0.0238) and men reporting a better physical score (P = 0.0002), the mean FACT-G total score did not differ by gender. However, the mean FACT-Leu total score was better among men versus women (P = 0.0223), primarily because the mean leukemia subscale score was significantly better among men (P <0.0001). Multivariate analysis qualitatively confirmed these findings.

Conclusions

Connect® CLL Registry results indicate that significant differences exist in certain HRQOL domains, as women reported greater levels of fatigue and worse functioning in physical domains.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sztankay M, Giesinger J, Holzner B (2011) Gender differences in quality of life in patients with haematological malignancies memo. Magazine of European Medical Oncology 4:224–226CrossRef Sztankay M, Giesinger J, Holzner B (2011) Gender differences in quality of life in patients with haematological malignancies memo. Magazine of European Medical Oncology 4:224–226CrossRef
2.
Zurück zum Zitat Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed
3.
Zurück zum Zitat Groenvold M, Klee MC, Sprangers MA, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient–observer agreement. J Clin Epidemiol 50:441–550CrossRefPubMed Groenvold M, Klee MC, Sprangers MA, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient–observer agreement. J Clin Epidemiol 50:441–550CrossRefPubMed
4.
Zurück zum Zitat Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B (2008) Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials—a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 44:1497–1506CrossRefPubMed Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B (2008) Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials—a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 44:1497–1506CrossRefPubMed
5.
Zurück zum Zitat Liu J, Mittendorf T, von der Schulenburg JM (2010) A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Investig 28:312–322CrossRef Liu J, Mittendorf T, von der Schulenburg JM (2010) A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Investig 28:312–322CrossRef
6.
Zurück zum Zitat Sajid MS, Tonsi A, Baig MK (2008) Health-related quality of life measurement. Int J Health Care Qual Assur 21:365–373CrossRefPubMed Sajid MS, Tonsi A, Baig MK (2008) Health-related quality of life measurement. Int J Health Care Qual Assur 21:365–373CrossRefPubMed
7.
Zurück zum Zitat Trask PC, Hsu MA, McQuellon R (2009) Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. Cancer J 15:435–440CrossRefPubMed Trask PC, Hsu MA, McQuellon R (2009) Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. Cancer J 15:435–440CrossRefPubMed
8.
Zurück zum Zitat Minasian LM, O'Mara AM, Reeve BB, Denicoff AM, Kelaghan J, Rowland JH, Trimble EL, National Cancer Institute (2007) Health-related quality of life and symptom management research sponsored by the National Cancer Institute. J Clin Oncol 25:5128–5132CrossRefPubMed Minasian LM, O'Mara AM, Reeve BB, Denicoff AM, Kelaghan J, Rowland JH, Trimble EL, National Cancer Institute (2007) Health-related quality of life and symptom management research sponsored by the National Cancer Institute. J Clin Oncol 25:5128–5132CrossRefPubMed
9.
Zurück zum Zitat Bottomley A, Aaronson NK (2007) European Organisation for Research and Treatment of Cancer international perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol 25:5082–5086CrossRefPubMed Bottomley A, Aaronson NK (2007) European Organisation for Research and Treatment of Cancer international perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol 25:5082–5086CrossRefPubMed
10.
Zurück zum Zitat Gribben JG (2008) Chronic lymphocytic leukemia: a historical perspective. Hematology Am Soc Hematol Educ Programs 2008:443CrossRef Gribben JG (2008) Chronic lymphocytic leukemia: a historical perspective. Hematology Am Soc Hematol Educ Programs 2008:443CrossRef
11.
Zurück zum Zitat Molica S (2005) Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma 46:1709–1714CrossRefPubMed Molica S (2005) Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma 46:1709–1714CrossRefPubMed
12.
Zurück zum Zitat Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL (2005) Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther 12:460–466CrossRefPubMed Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL (2005) Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther 12:460–466CrossRefPubMed
13.
Zurück zum Zitat Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R (2004) Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 year. Eur J Haematol 72:381–9CrossRefPubMed Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R (2004) Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 year. Eur J Haematol 72:381–9CrossRefPubMed
14.
Zurück zum Zitat Lanasa MC (2010) Novel insights into the biology of CLL. Hematology Am Soc Hematol Educ Program 2010:70–76CrossRefPubMed Lanasa MC (2010) Novel insights into the biology of CLL. Hematology Am Soc Hematol Educ Program 2010:70–76CrossRefPubMed
15.
Zurück zum Zitat Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012 Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2009_​pops09/​, based on November 2011 SEER data submission, posted to the SEER web site, 2012
16.
Zurück zum Zitat Catovsky D, Fooks J, Richards S (1989) Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC working party on leukaemia in adults. Br J Haematol 72:141–149CrossRefPubMed Catovsky D, Fooks J, Richards S (1989) Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC working party on leukaemia in adults. Br J Haematol 72:141–149CrossRefPubMed
17.
Zurück zum Zitat Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, Rabkin CS, Devesa SS, Linet MS (2007) Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 139:809–819CrossRefPubMed Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, Rabkin CS, Devesa SS, Linet MS (2007) Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 139:809–819CrossRefPubMed
18.
Zurück zum Zitat Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, Flowers CR (2011) Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk 11:498–506CrossRefPubMed Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, Flowers CR (2011) Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk 11:498–506CrossRefPubMed
19.
Zurück zum Zitat Molica S (2006) Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma 47:1477–1480CrossRefPubMed Molica S (2006) Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma 47:1477–1480CrossRefPubMed
20.
Zurück zum Zitat Prieto JM, Atala J, Blanch J, Carreras E, Rovira M, Cirera E, Gastó C (2004) Psychometric study of quality of life instruments used during hospitalization for stem cell transplantation. J Psychosom Res 57:201–11CrossRefPubMed Prieto JM, Atala J, Blanch J, Carreras E, Rovira M, Cirera E, Gastó C (2004) Psychometric study of quality of life instruments used during hospitalization for stem cell transplantation. J Psychosom Res 57:201–11CrossRefPubMed
21.
Zurück zum Zitat Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, Van’t Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M, EORTC-GELA H8 Trial Group (2009) Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol 10(12):1160–1170. doi:10.1016/S1470-2045(09)70258-X, Epub 2009 Oct 12CrossRefPubMed Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, Van’t Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M, EORTC-GELA H8 Trial Group (2009) Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol 10(12):1160–1170. doi:10.​1016/​S1470-2045(09)70258-X, Epub 2009 Oct 12CrossRefPubMed
22.
Zurück zum Zitat Arden-Close E, Pacey A, Eiser C (2010) Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma 51:628–40CrossRefPubMed Arden-Close E, Pacey A, Eiser C (2010) Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma 51:628–40CrossRefPubMed
23.
Zurück zum Zitat Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85:1186–1196CrossRefPubMed Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85:1186–1196CrossRefPubMed
24.
Zurück zum Zitat The EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef The EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef
25.
Zurück zum Zitat Webster K, Chivington K, Shonk C, Eremenco S, Yount S, Hahn E, van Gool R, Tallman M, Cella D (2002) Measuring quality of life (QOL) among patients with leukemia: the Functional Assessment of Cancer-Therapy-Leukemia (FACT-Leu). Qual Life Res 11:678, abstract Webster K, Chivington K, Shonk C, Eremenco S, Yount S, Hahn E, van Gool R, Tallman M, Cella D (2002) Measuring quality of life (QOL) among patients with leukemia: the Functional Assessment of Cancer-Therapy-Leukemia (FACT-Leu). Qual Life Res 11:678, abstract
26.
Zurück zum Zitat Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446–5456. doi:10.1182/blood-2007-06-093906, Epub 2008 Jan 23CrossRefPubMed Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446–5456. doi:10.​1182/​blood-2007-06-093906, Epub 2008 Jan 23CrossRefPubMed
27.
Zurück zum Zitat Shanafelt TD, Bowen DA, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG (2007) Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 139:255–264CrossRefPubMed Shanafelt TD, Bowen DA, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG (2007) Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 139:255–264CrossRefPubMed
28.
Zurück zum Zitat Shanafelt TD, Kay NE (2007) Comprehensive management of the CLL patient: a holistic approach. Hematology Am Soc Hematol Educ Program 2007:324–331CrossRef Shanafelt TD, Kay NE (2007) Comprehensive management of the CLL patient: a holistic approach. Hematology Am Soc Hematol Educ Program 2007:324–331CrossRef
Metadaten
Titel
Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia
verfasst von
Chris L. Pashos
Christopher R. Flowers
Neil E. Kay
Mark Weiss
Nicole Lamanna
Charles Farber
Susan Lerner
Jeff Sharman
David Grinblatt
Ian W. Flinn
Mark Kozloff
Arlene S. Swern
Thomas K. Street
Kristen A. Sullivan
Gale Harding
Zeba M. Khan
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 10/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1854-z

Weitere Artikel der Ausgabe 10/2013

Supportive Care in Cancer 10/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.